Maik Hauschild

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai et al. · New England Journal of Medicine · 2012 · 531 citations

Medicine, Oncology, Pharmacotherapy +17

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

Jens Huober, Gϋnter von Minckwitz, Carsten Denkert et al. · Breast Cancer Research and Treatment · 2010 · 294 citations

Medicine, Oncology, Pharmacology +17

Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

B. Gerber, Sibylle Loibl, Holger Eidtmann et al. · Annals of Oncology · 2013 · 152 citations · Full text

Medicine, Oncology, Pharmacology +17

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15